Effect of atorvastatin on type 2 diabetic dyslipidemia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 4, 2006, Pages 262-270

  Save, Vipul ^a,b   Patil, Neela ^a   Moulik, Nivedita ^a   Rajadhyaksha, Girish ^a  

^a Lokamanya Tilak Municipal Medical College and General Hospital   (India)

^b 2 Pragati CHS ^*  (India)

Author keywords

Antioxidant enzyme; apo B 100; Atorvastatin; Hyperlipidemia; LDL C; Malondialdehyde; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SCAVENGER; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PYRROLES; SUPEROXIDE DISMUTASE; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33845587183     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406295523     Document Type: Article

References (43)

1. American diabetes association clinical practice recommendation. Diabetes Care. 1998 ; 21: 179-182.
2. Manzato E, Zambon A, Lapolla A, et al. Lipoprotein abnormalities in well treated type II diabetic patients. Diabetes Care. 1993 ; 16: 469-475.
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
4. Consensus statement detection and management of lipid disorder in diabetes. Diabetes Care. 1993 ; 16: 106-112.
5. Gotto AM Jr, Whitney E, Stein EA. Relation between baseline and on-treatment lipid parameter and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000 ; 101: 477-484.
6. Brunzell JD, Hazzard WR, Motuskly AG, et al. Evidence for diabetes mellitus and genetic forms of hypertriglyceridemia as independent entities. Metabolism. 1975 ; 24: 1115-1121.
7. Pyorala K, Pederson TR, Kjekshus J. Cholesterol lowering with simvastatin improves prognosis of diabetes patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997 ; 20: 614-620.
8. Matsuzki M, Kita T, Mabuchi H, et al. Larger scale cohort study of the relationship between serum cholesterol concentration and coronary events with low dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002 ; 66: 1087-1095.
9. Alkawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor cerivastatin suppresses growth of macrophages expressing matrix metalloproteinase and tissue factor in vivo and in vitro. Circulation. 2001 ; 103: 276-283.
10. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 ; 352: 20-28.
11. Riesen WF, Engler H, Rish M, et al. Short term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002 ; 23: 794-799.
12. McCord JM, Fridovich I. Superoxide dismutase on enzymatic function for erythrocuprein. J Biol Chem. 1969 ; 22: 6049-6055.
13. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988 ; 34: 497-500.
14. Boyne AF, Ellman GL. A methodology for analysis of tissue sulfhydryl components. Anal Biochem. 1972 ; 46: 639-653.
15. Paglia DE, Valentine WN. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Clin Chem. 1967 ; 70: 158-169.
16. William HH, Michael JP, William BJ. Glutathione S-transferase: the first enzymatic step in mercapturic acid formation. J Biol Chem. 1974 ; 249: 7130-7139.
17. Sasikala M, Subramanyam C, Sadasivudu B. Early oxidative change in low density lipoproteins during progressive chronic renal failure. Indian J Clin Biochem. 1999 ; 14: 176-183.
18. Jones P, Kafonek S, Laurora I. Comparative efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998 ; 81: 582-587.
19. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696.
20. Sever PS, Poulter NR, Dahlof B. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Diabetes Care. 2005 ; 28: 1151-1157.
21. Athyros VG, Papageorgiou AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology. 2003 ; 54: 679-690.
22. Black DM, Bakker-Arkema R, Heinonen T, et al. Efficacy and safety of atorvastatin in hyperlipidemic patients with concurrent hypertension or non insulin dependent diabetes mellitus. J Hypertens. 1998 ; 16 (suppl 2). S233 - S233.
23. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-C by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin a new HMG CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995 ; 15: 678-682.
24. Japan Cholesterol Lowering Atorvastatin Study Group. A comparative study of the effect of atorvastatin, a new HMG-CoA reductase inhibitor with pravastatin in primary hyperlipidemia patients. Prog Med. 1998 ; 18: 2251-2300.
25. Japan Cholesterol Lowering Atorvastatin Study Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol. 1997 ; 79: 1248-1252.
26. Atorvastatin Study Group I, Davidson M, McKenney J, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997 ; 79: 1475-1481.
27. Dart A, Jerms G, Nicholson G, et al. A multicentre, double-bind, one year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997 ; 80: 39-44.
28. Davidson MH, Ma PTC, Stein E. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa and IIb hypercholesterolemia. J Am Coll Cardiol. 2001 ; 37 (suppl A). 292A - 292A. Abstract 1261-175.
29. Schoojans K, Peinado-Onsurbe J, Fruchart JC, et al. 3-hydroxy-3- methylglutaryl CoA reductase inhibitors reduce serum TG levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999 ; 452: 160-164.
30. Geneviève M, Hélène D, Christophe B, et al. Statin induced inhibition of the Rho-signaling pathway activates PPAR-alpha and induces HDL apoA-I. J Clin Invest. 2001 ; 107: 1423-1432.
31. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis. 1998 ; 141: S57 - S62.
32. Grundy SM. Consensus statement role of therapy with "statin" in patients with hypertriglyceridemia. Am J Cardiol. 1998 ; 81: 1B - 6B.
33. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 1990 ; 10: 668-671.
34. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990 ; 13: 153-169.
35. Mitchell A, Fidge N, Grififths P. The effect of the HMG CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat. Biochem Biophys Acta. 1993 ; 1167: 9-14.
36. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. J Clin Pathol. 2004 ; 57: 728-734.
37. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 ; 361: 2005-2016.
38. Harrison DG. Endothelial function and oxidative stress. Clin Cardiol. 1997 ; 20 (11 suppl 2). II-11-7 - II-11-7.
39. Passi S, Stancato A, Aleo E, et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 2003 ; 18: 113-124.
40. Yilmaz MI, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004 ; 98: 119-127.
41. Sven W, Ulrich L, Kirsten M, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002 ; 22: 300-305.
42. Koichi S, Nobuo F, Katsunori W. Effects of atorvastatin therapy on the low density lipoprotein sub fraction, remnant like particles cholesterol, and oxidized low density lipoprotein within 2 week in hypercholesterolemic patients. Circ J. 2003 ; 67: 866-870.
43. Nishi K, Uno M, Fukuzawa K, et al. Clinicopathological significance of lipid peroxidation in carotid plaques. Atherosclerosis. 2002 ; 160: 289-296.